BRAF and neoplasm: However, another study on the impact of primary tumor sidedness on treatment outcomes for patients receiving bevacizumab-based therapies found that the efficacy of bevacizumab in patients with a left-sided tumor is superior to efficacy for right-sided tumors, particularly in a wild-type RAS/BRAF subgroup 25.